Evidence map›Paper›PMID 40939877›Full record

ArticleSLAS technology2025

High-throughput cytokine detection platform for evaluation of chemical induced microglial activation.

Shu Yang, Kelly E Carstens, Ibukunoluwa Ipaye, Xing Chen, Helena T Hogberg, Nicole Kleinstreuer, Thomas B Knudsen, Menghang Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shu YangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Kelly E CarstensCenter for Computational Toxicology and Exposure, Office of Research & Development, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.
Ibukunoluwa IpayeDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Xing ChenDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Helena T HogbergNational Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.
Nicole KleinstreuerNational Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.
Thomas B KnudsenDept of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Menghang XiaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA. Electronic address: mxia@mail.nih.gov.

Funding

Toxicology in the 21st Century Program (Tox21) - Systems ToxicologyZIATR000038 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI XIA, MENGHANG · 2015 to 2025
$5.7M
Intramural NIH HHS ZIA TR000038
6 · The paper itself

Abstract

Environmental chemical exposure, such as pesticides and heavy metals, may contribute to neurodegenerative disorders through neuroinflammation. This study aims to identify suitable in vitro microglial models for assessing cytokine responses to potential neurotoxicants, particularly focusing on human induced pluripotent stem cell-derived microglia (hiMG). In this study, we evaluated the cytokine secretion profiles of four microglial cell types-hiMG, HMC3, IM-HM, and BV2-upon stimulation with lipopolysaccharides (LPS) using cytokine arrays. Our findings showed cytokine response patterns in hiMG cells that most closely resemble in vivo conditions, with significant increases in interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels, the latter being uniquely expressed after LPS treatment. Consequently, we developed a homogeneous time-resolved fluorescence (HTRF) assay platform in a 1536-well plate format for high-throughput screening of environmental chemicals using hiMG cells. After LPS treatment, the assay window for secretion of IL-6 and TNF-α increased 3.71-fold and 2.62-fold over the vehicle control group, respectively, with respective EC

Indexed as

CytokinesHigh-Throughput Screening AssaysMicrogliaCell LineHumansInduced Pluripotent Stem CellsLipopolysaccharidesTumor Necrosis Factor-alphaCytokinesLipopolysaccharidesTumor Necrosis Factor-alphaCytokineHigh-throughput screeningIL-6MicrogliaNeuroinflammationTNF-α

Identifiers

PMID40939877
PMCPMC12697230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.